samedan logo
 
 
spacer
home > white papers > The Promise and Challenge of Adaptive Design in Oncology Trials - Medpace
WHITE PAPERS
logo_Medpace.JPG

Medpace

phone +1.513.579.9911
email info@medpace.com
web http://www.medpace.com
email Medpace 5375 Medpace Way, Cincinnati, Ohio, 45227

The Promise and Challenge of Adaptive Design in Oncology Trials

Clinical oncology trials are more complex and time consuming than those in any other therapeutic area and failure rates are frustratingly high. Given the urgent need for new oncologic therapies, sponsors are eager to find more effective ways to conduct clinical research.

Incorporating adaptive design methodologies into clinical trials can reduce costs and enhance efficiency while maintaining trial integrity. They can also reduce the number of patients on placebo and sub-therapeutic doses. In light of this promise, regulatory bodies have created guidelines supportive of adaptive design.


The Promise and Challenge of Adaptive Design in Oncology Trials
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

Zenith Technologies Wins ‘Supplier of the Year’ at Pharma Industry Awards 2018

Zenith Technologies, a world leader in delivering manufacturing software to the life sciences industry, has been named ‘Pharma Supplier of the Year’ at the prestigious 2018 Pharma Industry Awards.
More info >>


White Papers

Industry Events

ASGCT 22nd Annual Meeting

29 April - 2 May 2019, Washington Hilton, Washington, D.C

The 2019 ASGCT Annual Meeting is expected to be the largest in Society history, eclipsing the mark set by the 2018 meeting just last year. Join more than 3,500 researchers, clinicians, advocates, and industry leaders in discovering the latest science and technology surrounding gene and cell therapy.
More info >>


©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement